medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-10-92-96medsovet-2538Research ArticleОНКОГЕМАТОЛОГИЯONCOHEMATOLOGYВозможности терапии рецидива хронического лимфолейкоза, отягощенного аутоиммунными осложнениями. Данные литературы и собственное наблюдениеPossibilities of therapy recurrent b-cell chronic lymphocytic leukemia associated with autoimmune complications: data from literature and personal observationГорячеваС. Р.GoryachevaS. R.

Кандидат медицинских наук

СорокинаТ. В.SorokinaT. V.

Кандидат медицинских наук

Аль-РадиЛ. С.Al-RadiL. S.

Кандидат медицинских наук

ШерстневА. А.SherstnevA. M.МоисееваТ. Н.MoiseevaT. N.

Кандидат медицинских наук

ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава РоссииРоссияNational medical research center of Hematology, Ministry of health of RussiaRussian Federation2018180720180109296Copyright © Горячева С.Р., Сорокина Т.В., Аль-Ради Л.С., Шерстнев А.А., Моисеева Т.Н., 20182018Горячева С.Р., Сорокина Т.В., Аль-Ради Л.С., Шерстнев А.А., Моисеева Т.Н.Goryacheva S.R., Sorokina T.V., Al-Radi L.S., Sherstnev A.M., Moiseeva T.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2538

Приведено описание клинического наблюдения успешной терапии ибрутинибом рецидива хронического лимфолейкоза, отягощенного аутоиммунными осложнениями. Обсуждаются причины возникновения аутоиммунных осложнений ХЛЛ, их влияние на прогноз заболевания, а также тактика ведения подобных пациентов.

The description of the clinical observation of the successful therapy with ibrutinib recurrent B-cell chronic lymphocytic leukemia associated with autoimmune complications is given. The reasons for occurrence the autoimmune complications of CLL, their effect on the disease prognosis as well as the tactics of conducting similar patients have been considered.

хронический лимфолейкоз (ХЛЛ)аутоиммунные осложнения ХЛЛаутоиммунная гемолитическая анемия (АИГА)иммунная тромбоцитопения (ИТП)иммунные цитопенииибрутинибlymphocytic leukemia (CLL)the autoimmune complications of CLLautoimmune hemolytic anemia (AIHA)immune thrombocytopenia (ITP)autoimmune cytopenias (AIC)ibrutinibReferencesRai KR, Jain P. Chronic lymphocytic leukemia – Then and now. Am J Hematol, 2016; 91(3): 33040. doi: 10.1002/ajh24282.Rai KR, Jain P. Chronic lymphocytic leukemia – Then and now. Am J Hematol, 2016; 91(3): 33040. doi: 10.1002/ajh24282.Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment – driven immune suppression in B-cell malignancy. Biochim Biophys Acta, 2016, 1863(3): 471-82. doi 10.1016/j.bbamcr.2015.11.003.Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment – driven immune suppression in B-cell malignancy. Biochim Biophys Acta, 2016, 1863(3): 471-82. doi 10.1016/j.bbamcr.2015.11.003.Best OG, Crassini K, Freeman JA, Mulligan S. CLL Australian Research Consortium. The clinical significance of hypogemmaglobuliaemia and serum ummunoglobulin G subclass deficiency in patients with chronic lymphocytia leukemia (CLL). Scand J Infect Dis, 2013, 45(9): 729. doi: 10.3109/00365548.2013.809477.Best OG, Crassini K, Freeman JA, Mulligan S. CLL Australian Research Consortium. The clinical significance of hypogemmaglobuliaemia and serum ummunoglobulin G subclass deficiency in patients with chronic lymphocytia leukemia (CLL). Scand J Infect Dis, 2013, 45(9): 729. doi: 10.3109/00365548.2013.809477.Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin North Am, 2013, 27(2): 207-35. doi: 10.1016/j.hoc.2013.01.003.Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin North Am, 2013, 27(2): 207-35. doi: 10.1016/j.hoc.2013.01.003.Dearden C. Disease – specific complications of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program, 2008: 5-406.Dearden C. Disease – specific complications of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program, 2008: 5-406.Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, Mc Kenna KM, et al. Macrophages eat cancer cells using their own calreticulin as a guide, Roles of TLR and Btk. Proceedings of the National Academy of Sciences of the United States of America, 2015 Feb 17, 112(7): 2145-2150.Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, Mc Kenna KM, et al. Macrophages eat cancer cells using their own calreticulin as a guide, Roles of TLR and Btk. Proceedings of the National Academy of Sciences of the United States of America, 2015 Feb 17, 112(7): 2145-2150.Hodgsen K, Ferrer G, Montserrat E, and Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica, 2011, 96(5): 752-761. doi: 10.3324/haematol.2010.036152.Hodgsen K, Ferrer G, Montserrat E, and Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica, 2011, 96(5): 752-761. doi: 10.3324/haematol.2010.036152.Visco C, Ruggeri M, Giaretta I, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood, 2008, 111(3): 1110-6.Visco C, Ruggeri M, Giaretta I, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood, 2008, 111(3): 1110-6.Dührsen V, Augener W, Zwinger T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disoders: analysis of 637 caseand comparison with myeloproliferative diseases. Br J Haematol, 1987, 67(2): 235-9.Dührsen V, Augener W, Zwinger T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disoders: analysis of 637 caseand comparison with myeloproliferative diseases. Br J Haematol, 1987, 67(2): 235-9.• Hamblin TJ. Autoimmune complicatious of chronic lymphocytic leukemia. Semin Oncol, 2006, Apr, 33(2): 230-239.• Hamblin TJ. Autoimmune complicatious of chronic lymphocytic leukemia. Semin Oncol, 2006, Apr, 33(2): 230-239.• Mauro FR, Foa R, Cerretti R, et al. Autuimmune cytopenias in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood, 2000 May 1, 95(9): 2786-2792.• Mauro FR, Foa R, Cerretti R, et al. Autuimmune cytopenias in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood, 2000 May 1, 95(9): 2786-2792.Byrd J, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med, 2013, 369(1): 32-42. doi: 10.1056/NEJMoal215637.Byrd J, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med, 2013, 369(1): 32-42. doi: 10.1056/NEJMoal215637.Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic lymphocytic leukemia. Am J Blood Res, 2013, 3(1): 71-83.Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic lymphocytic leukemia. Am J Blood Res, 2013, 3(1): 71-83.Cheson BD, Byrd JC, Rai KR, Kay NE, O’Brien SM, Flinn IW, et. al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol, 2012, 30(23): 2820-2. doi: 10.1200/JCO.2012.43.3748.Cheson BD, Byrd JC, Rai KR, Kay NE, O’Brien SM, Flinn IW, et. al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol, 2012, 30(23): 2820-2. doi: 10.1200/JCO.2012.43.3748.Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving singleagent ibrutinib. Blood, 2015, 125(16): 2497-506. doi: 10.1182/blood-2014-10-606038.Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving singleagent ibrutinib. Blood, 2015, 125(16): 2497-506. doi: 10.1182/blood-2014-10-606038.Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. RESONATE Investigators. Ibrutinib versus Ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med, 2014, 371(3): 213-23. doi: 10.1056/NEJMoa1400376.Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. RESONATE Investigators. Ibrutinib versus Ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med, 2014, 371(3): 213-23. doi: 10.1056/NEJMoa1400376.Savchenko VG ed. Programs of treatment of disease of the blood system: the Collection of diagnostic algorithms and protocols for the treatment of diseases of the blood system. Moscow: Practice, 2012.Savchenko VG ed. Programs of treatment of disease of the blood system: the Collection of diagnostic algorithms and protocols for the treatment of diseases of the blood system. Moscow: Practice, 2012.Emma D. Dreeks. Ibrutinib: a review in chronic lymphocytic leukemia. Drugs, 2017, 77: 225-236. doi 10.1007/s40265-017-0695.Emma D. Dreeks. Ibrutinib: a review in chronic lymphocytic leukemia. Drugs, 2017, 77: 225-236. doi 10.1007/s40265-017-0695.Montillo M, O’Brien S, Tedeschi A, Hillmen P, Dearden C, Gill D, et al. Autoimmune Hemolyctic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report. Blood, 2014 Dec 06, 124(21): 5654-5654.Montillo M, O’Brien S, Tedeschi A, Hillmen P, Dearden C, Gill D, et al. Autoimmune Hemolyctic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report. Blood, 2014 Dec 06, 124(21): 5654-5654.Maura F, Visco C, Falisi E, Reda G, Fabris S, Agnelli L, et al. B-cell receptor configuration and adverse cytogenetic are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. American journal of hematology, 2013 Jan, 88(1): 32-36.Maura F, Visco C, Falisi E, Reda G, Fabris S, Agnelli L, et al. B-cell receptor configuration and adverse cytogenetic are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. American journal of hematology, 2013 Jan, 88(1): 32-36.Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leukemia & lymphoma, 2009 Aug, 50(8): 1261-1268.Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leukemia & lymphoma, 2009 Aug, 50(8): 1261-1268.Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chrinoc lymphocytic leukemia by malignant B cells. Blood, 2005 Mar 1, 105(5): 2007-2015.Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chrinoc lymphocytic leukemia by malignant B cells. Blood, 2005 Mar 1, 105(5): 2007-2015.Centola M, Lin K, Sutton C, Berenson JR, Kunkel LA, Rosen L, et al. Production of antierithrocyte antibodies by leukemic and nonleukemic B cells in chronic lymphocytic leukemia patients. Leukemia & lymphoma, 1996 Feb, 20(5-6): 465-469.Centola M, Lin K, Sutton C, Berenson JR, Kunkel LA, Rosen L, et al. Production of antierithrocyte antibodies by leukemic and nonleukemic B cells in chronic lymphocytic leukemia patients. Leukemia & lymphoma, 1996 Feb, 20(5-6): 465-469.Manda S, Dunbar N, Marx-Wood CR, Danilov AV. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol, 2015, 170: 734-736.Manda S, Dunbar N, Marx-Wood CR, Danilov AV. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol, 2015, 170: 734-736.Bernard RSt, Hsia CC. Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Ann Hematol, 2015, 94: 2077-2079.Bernard RSt, Hsia CC. Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Ann Hematol, 2015, 94: 2077-2079.Molica S, Levato L, Mirabelli R. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature. Leuk Lymphoma, 2016, 57: 735-737.Molica S, Levato L, Mirabelli R. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature. Leuk Lymphoma, 2016, 57: 735-737.Cavazzini F, Lista E, Quaglia FM, et al. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. Leuk Lymphoma, 2016 March, 21: 1-4.Cavazzini F, Lista E, Quaglia FM, et al. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. Leuk Lymphoma, 2016 March, 21: 1-4.Vitale C, Ahn IE, Sivina M, Ferrajoli A, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica, 2016 March, 24, pii: haematol.2015.138289.Vitale C, Ahn IE, Sivina M, Ferrajoli A, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica, 2016 March, 24, pii: haematol.2015.138289.Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Luekemia, 2016 February, 30: 346-350.Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Luekemia, 2016 February, 30: 346-350.Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med, 2015 December, 73: 2425-2437.Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med, 2015 December, 73: 2425-2437.Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in model of autoimmune disease and B-cell malignancy. Proc Nati Acad Sci U S A, 2010, 107: 13075-13080.Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in model of autoimmune disease and B-cell malignancy. Proc Nati Acad Sci U S A, 2010, 107: 13075-13080.Molica S, Polliak A. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. Leukemia Research, 2016 November, 50: 31-36.Molica S, Polliak A. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. Leukemia Research, 2016 November, 50: 31-36.

The authors declare that there are no conflicts of interest present.